Lexaria Bioscience Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 7

Employees

  • Stock Symbol
  • LEXX

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $4.31
  • (As of Tuesday Closing)

Lexaria Bioscience General Information

Description

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 740 McCurdy Road
  • Suite 100
  • Kelowna, British Columbia V1X 2P7
  • Canada
+1 (250)
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Drug Delivery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 740 McCurdy Road
  • Suite 100
  • Kelowna, British Columbia V1X 2P7
  • Canada
+1 (250)

Lexaria Bioscience Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lexaria Bioscience Stock Performance

As of 17-Nov-2026, Lexaria Bioscience’s stock price is $4.31. Its current market cap is $8.81M with 2.11M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.31 $4.44 $2.43 - $21.60 $8.81M 2.11M 72.9K -$5.10

Lexaria Bioscience Financials Summary

As of 31-May-2026, Lexaria Bioscience has a trailing 12-month revenue of $194K.

In Thousands,
USD
TTM 31-May-2026 FY 2025 31-Aug-2025 FY 2024 31-Aug-2024 FY 2023 31-Aug-2023
EV 9,355 12,324 53,079 4,883
Revenue 194 706 464 226
EBITDA (7,665) (11,827) (5,747) (6,610)
Net Income (7,732) (11,902) (5,795) (6,665)
Total Assets 4,781 4,175 8,868 3,084
Total Debt 87 109 137 164
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lexaria Bioscience Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lexaria Bioscience‘s full profile, request access.

Request a free trial

Lexaria Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lexaria Bioscience Investments & Acquisitions (3)

Lexaria Bioscience’s most recent deal was a Secondary Transaction - Private with Poviva Tea for . The deal was made on 25-Oct-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Poviva Tea 25-Oct-2017 Secondary Transaction - Private Buildings and Property
Ambarii Trade 10-Apr-2017 Joint Venture Drug Discovery
Poviva Tea 12-Dec-2014 Merger/Acquisition Buildings and Property
To view Lexaria Bioscience’s complete investments and acquisitions history, request access »

Lexaria Bioscience ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

44.77 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Lexaria Bioscience’s complete esg history, request access »

Lexaria Bioscience FAQs

  • When was Lexaria Bioscience founded?

    Lexaria Bioscience was founded in 2004.

  • Where is Lexaria Bioscience headquartered?

    Lexaria Bioscience is headquartered in Kelowna, Canada.

  • What is the size of Lexaria Bioscience?

    Lexaria Bioscience has 7 total employees.

  • What industry is Lexaria Bioscience in?

    Lexaria Bioscience’s primary industry is Other Healthcare Technology Systems.

  • Is Lexaria Bioscience a private or public company?

    Lexaria Bioscience is a Public company.

  • What is Lexaria Bioscience’s stock symbol?

    The ticker symbol for Lexaria Bioscience is LEXX.

  • What is the current stock price of Lexaria Bioscience?

    As of 17-Nov-2026 the stock price of Lexaria Bioscience is $4.31.

  • What is the current market cap of Lexaria Bioscience?

    The current market capitalization of Lexaria Bioscience is $8.81M.

  • What is Lexaria Bioscience’s current revenue?

    The trailing twelve month revenue for Lexaria Bioscience is $194K.

  • What is Lexaria Bioscience’s annual earnings per share (EPS)?

    Lexaria Bioscience’s EPS for 12 months was -$5.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process